Evidence map›Paper›PMID 35913095›Full record

ArticleJournal of clinical and experimental neuropsychology2022

Development of the Colorado posterior cortical questionnaire within an Alzheimer's disease study cohort.

Samantha K Holden, Victoria S Pelak, Trevor Sooy, Kate S Heffernan, Brice V McConnell, Peter S Pressman, Brianne M Bettcher

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical and experimental neuropsychology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Samantha K HoldenDepartment of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Victoria S PelakDepartment of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Trevor SooyDepartment of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Kate S HeffernanNeuroscience Graduate Program, Division of Biological and Biomedical Sciences, Emory Laney Graduate School, Atlanta, GA, USA.
Brice V McConnellDepartment of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Peter S PressmanDepartment of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Brianne M BettcherDepartment of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
University of Colorado Denver · USEmory and Henry College · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Investigating the Contribution of Peripheral versus Central Nervous System Immune Dysfunction to Cognitive AgingR01AG058772 · NIA · UNIVERSITY OF COLORADO DENVER · PI BETTCHER, BRIANNE MAGOUIRK · 2019 to 2023
$3.7M
NCATS NIH HHS UL1 TR002535NIA NIH HHS R01 AG058772
6 · The paper itself

Abstract

introductionNon-amnestic presentations of neurodegenerative dementias, including posterior- and visual-predominant cognitive forms, are under-recognized. Specific screening measures for posterior cortical symptoms could allow for earlier, more accurate diagnosis and directed treatment.

methodsBased on clinical experience with posterior cortical atrophy evaluations, high-yield screening questions were collected and organized into a 15-item self-report questionnaire, titled the Colorado Posterior Cortical Questionnaire (CPC-Q). The CPC-Q was then piloted within a longitudinal cohort of cognitive aging, including 63 older adults, including healthy older adults (n = 33) and adults with either amnestic Alzheimer's disease (n = 21) or posterior cortical atrophy (PCA, n = 9).

resultsThe CPC-Q demonstrated acceptable psychometric properties (internal consistency, α = 0.89; mean item-total correlation = 0.62), correlated strongly with visuospatial measures on cognitive testing (p < 0.001), and could distinguish PCA from non-PCA groups (p < 0.001; AUC 0.95 (95% CI 0.88, 1.0)).

conclusionsThe CPC-Q captured posterior cortical symptoms in older adults, using a gold standard of expert consensus PCA diagnosis. Future studies will validate the CPC-Q in a larger cohort, with recruitment of additional PCA participants, to evaluate its convergent and discriminant validity more thoroughly. As a short, self-report tool, the CPC-Q demonstrates potential to improve detection of non-amnestic neurodegenerative dementias in the clinical setting.

Indexed as

Alzheimer DiseaseAgedAtrophyCerebral CortexColoradoHumansSurveys and QuestionnairesAlzheimer’s diseaseCognitive impairmentposterior cortical atrophyscreeningvisuospatial

Identifiers

PMID35913095
PMCPMC9420807
OpenAlexW4289314364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.